NH130

NH130

Clinical data
Other names	NH-130
Routes of administration	Oral[1][2]
Drug class	Serotonin 5-HT2A receptor antagonist; Antipsychotic
Pharmacokinetic data
Onset of action	3.0–4.5 hours (TmaxTooltip time to peak levels
Elimination half-life	13.7–18.2 hours[2]

NH130 is a highly selective serotonin 5-HT_2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis.^[3][1][4][2] It is taken orally.^[1][2] The drug's time to peak levels is 3.0 to 4.5 hours and its elimination half-life is 13.7 to 18.2 hours.^[2] NH130 is under development by Jiangsu Nhwa Pharmaceutical in China.^[3][1][2] As of November 2025, it is in phase 2 clinical trials.^[3]

See also

• Serotonin 5-HT_2A receptor antagonist

References

1. "NH-130 Drug Profile". Ozmosi. Retrieved 18 January 2026.
2. Zhang K, Zhao S, Du J, Zhang L (2024). "Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling". Frontiers in Pharmacology. 15 1474868. doi:10.3389/fphar.2024.1474868. PMC 11424876. PMID 39329116. Following the success of pimavanserin, the search for new molecules with enhanced efficacy and an improved safety profile for treating PDP began. In Phase 1 clinical trial (CTR20230409), healthy volunteers received the compound NH130, a highly selective inverse agonist of the 5-HT2AR designed to mimic pimavanserin. The results confirmed NH130's favourable safety and tolerability. Based on these findings, further optimization of the compound and Phase 2 studies in patients with PDP are planned (K. Zhang et al., 2024).
3. "Delving into the Latest Updates on NH-130 with Synapse". Synapse. 21 November 2025. Retrieved 18 January 2026.
4. Fryc M, Kluzik D, Czopek A, Jończyk J, Zagórska A (November 2025). "Serotonin 2A (5-HT_2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases". Neuropharmacology. 279 110622. doi:10.1016/j.neuropharm.2025.110622. PMID 40752586.